Information Provided By:
Fly News Breaks for January 10, 2020
Jan 10, 2020 | 08:38 EDT
Raymond James analyst Elliot Wilbur initiated coverage of Elanco (ELAN) with a Market Perform rating. In a research note to investors, Wilbur says Elanco remains well positioned to capitalize on favorable animal therapeutics growth dynamics, particularly following the acquisition of Bayer's (BAYRY) animal health business, but says that a number of factors, including generic Rumensin competition and slower rebound in swine markets from African swine fever impact may temper near-term growth rates, limiting multiple expansion.
News For ELAN From the Last 2 Days
There are no results for your query ELAN